- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-UBE2C/ UBCH10/ dJ447F3.2 monoclonal antibody
Anti-UBE2C/ UBCH10/ dJ447F3.2 antibody for FACS & in-vivo assay
Go to UBE2C/UBE2C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP2372-Ab-1/ GM-Tg-hg-MP2372-Ab-2 | Anti-Human UBE2C monoclonal antibody | Human |
| GM-Tg-rg-MP2372-Ab-1/ GM-Tg-rg-MP2372-Ab-2 | Anti-Rat UBE2C monoclonal antibody | Rat |
| GM-Tg-mg-MP2372-Ab-1/ GM-Tg-mg-MP2372-Ab-2 | Anti-Mouse UBE2C monoclonal antibody | Mouse |
| GM-Tg-cynog-MP2372-Ab-1/ GM-Tg-cynog-MP2372-Ab-2 | Anti-Cynomolgus/ Rhesus macaque UBE2C monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP2372-Ab-1/ GM-Tg-felg-MP2372-Ab-2 | Anti-Feline UBE2C monoclonal antibody | Feline |
| GM-Tg-cang-MP2372-Ab-1/ GM-Tg-cang-MP2372-Ab-2 | Anti-Canine UBE2C monoclonal antibody | Canine |
| GM-Tg-bovg-MP2372-Ab-1/ GM-Tg-bovg-MP2372-Ab-2 | Anti-Bovine UBE2C monoclonal antibody | Bovine |
| GM-Tg-equg-MP2372-Ab-1/ GM-Tg-equg-MP2372-Ab-2 | Anti-Equine UBE2C monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP2372-Ab-1/ GM-Tg-hg-MP2372-Ab-2; GM-Tg-rg-MP2372-Ab-1/ GM-Tg-rg-MP2372-Ab-2; GM-Tg-mg-MP2372-Ab-1/ GM-Tg-mg-MP2372-Ab-2; GM-Tg-cynog-MP2372-Ab-1/ GM-Tg-cynog-MP2372-Ab-2; GM-Tg-felg-MP2372-Ab-1/ GM-Tg-felg-MP2372-Ab-2; GM-Tg-cang-MP2372-Ab-1/ GM-Tg-cang-MP2372-Ab-2; GM-Tg-bovg-MP2372-Ab-1/ GM-Tg-bovg-MP2372-Ab-2; GM-Tg-equg-MP2372-Ab-1/ GM-Tg-equg-MP2372-Ab-2 |
| Products Name | Anti-UBE2C monoclonal antibody |
| Format | mab |
| Target Name | UBE2C |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-UBE2C benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species UBE2C/ UBCH10/ dJ447F3.2 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLP000350 | human UBE2C Lentivirus plasmid |
| ORF Viral Vector | vGMLP000350 | human UBE2C Lentivirus particle |
| ORF Viral Vector | pGMAAV000329 | house mouse Ube2c AAV plasmid |
| ORF Viral Vector | pGMLPm000232 | mouse Ube2c Lentivirus plasmid |
| ORF Viral Vector | vGMAAV000329 | house mouse Ube2c AAV particle |
| ORF Viral Vector | vGMLPm000232 | mouse Ube2c Lentivirus particle |
Target information
| Target ID | GM-MP2372 |
| Target Name | UBE2C |
| Gene ID | 11065,68612,296368,709380,485898,101087052,506962,100056334 |
| Gene Symbol and Synonyms | 1110015A16Rik,D2Ertd695e,dJ447F3.2,UBCH10,UBE2C |
| Uniprot Accession | O00762,Q32PA5 |
| Uniprot Entry Name | UBE2C_HUMAN,UBE2C_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | Breast Cancer |
| Gene Ensembl | ENSG00000175063 |
| Target Classification | N/A |
The target: UBE2C, gene name: UBE2C, also named as UBCH10, dJ447F3.2. The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, and ubiquitin-protein ligases. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. The encoded protein is required for the destruction of mitotic cyclins and for cell cycle progression, and may be involved in cancer progression. Multiple transcript variants encoding different isoforms have been found for this gene. Pseudogenes of this gene have been defined on chromosomes 4, 14, 15, 18, and 19. [provided by RefSeq, Aug 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
